

PDR.net

Online Updates • FDA-approved Drug Alerts • CME

Find authenticated court documents without watermarks at docketalarm.com.

Δ



CEO: Edward Fotsch, MD President: David Tanzer Chief Medical Officer: Christine Côté, MD Chief Technology Officer: Nick Krym Chief Financial Officer: Dawn Carfora

Vice President, Product Management & Operations: Valerie Berger Vice President, Emerging Products: Debra Del Guidice Vice President, Corporate Development, Copy Sales & General Counsel: Andrew Gelman Vice President, Sales: John Loucks Vice President, Marketing: Julie Baker Vice President, Business Development: Tom Dieker

Director of Sales: Eileen Bruno Business Manager: Karen Fass Senior Account Executives: Marjorie A. Jaxel, Philip Molinaro Account Executives: Nick W. Clark, Carlos Cornejo, Caryn Trick Associate Account Executives: Carol Levine, Janet Wallendal Sales Coordinator: Dawn McPartland

Senior Director, Operations & Client Services: Stephanie Struble Senior Director, Editorial & Publishing: Bette Kennedy Director, Clinical Services: Sylvia Nashed, PharmD Director, Marketing: Kim Marich Senior Manager, Client Services: Lisa Caporuscio Manager, Clinical Services: Nermin Kerolous, PharmD Senior Drug Information Specialist, Database Management: Christine Sunwoo, PharmD Senior Drug Information Specialist, Product Development: Anila Patel, PharmD Drug Information Specialists: Peter Leighton, PharmD; Kristine Mecca, PharmD; See-Won Seo, PharmD Manager, Editorial Services: Lori Murray Associate Editor: Jennifer Reed Manager, Art Department: Livio Udina Electronic Publication Designer: Carrie Spinelli Faeth Director, PDR Production: Jeffrey D. Schaefer Associate Director, Manufacturing & Distribution: Thomas Westburgh Production Manager, PDR: Steven Maher **Operations Database Manager: Noel Deloughery**


Senior Index Editor: Allison O'Hare Index Editor: Julie L. Cross Senior Production Coordinator: Yasmin Hemández Production Coordinators: Eric Udina, Christopher Whalen Format Editor: Dan Cappello Fulfillment Management Specialist: Gary Lew Manager, Customer Service: Todd Taccetta

Copyright © 2010 PDR Network, LLC. Published by PDR Network, LLC at Montvale, NJ 07645-1725. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. Physicians' Desk Reference® and PDR® are registered trademarks of PDR Network, LLC. PDR® for Ophthalmic Medicines; PDR® for Nonprescription Drugs, Dietary Supplements, and Herbs; PDR® Pharmacopoeia; and PDR® Electronic Library are trademarks of PDR Network, LLC.

ISBN: 978-1-56363-780-3

2864/PROGENICS • RELISTOR

sure the tip of the needle is in the fluid. Slowly pull back on the plunger (Figure 11) to the mark that matches your prescribed dose (usually the 0.4 mL mark which is an 8 mg dose or the 0.6 mL mark which is a 12 mg dose).



You may see some fluid or bubbles inside the vial when the syringe is filled. This is normal. With the needle still in the vial, gently tap the syringe to make any air bubbles rise to the top (Figure 12).

8.





Figure 12

Slowly push the plunger up until all air bubbles are out 9. of the syringe (Figure 13).



10. Make sure the tip of the needle is in the fluid. Slowly pull back the plunger to draw the right amount of liquid back into the syringe (Figure 14).




Figure 14

Check to be sure that you have the right dose of RELISTOR in the syringe. Note: A small air bubble may stay in the syringe. This

- is okay and it will not affect the dose of medicine in the yringe
- 11. Slowly withdraw the needle from the vial (do not touch the needle or allow the needle to touch any surface). Safely throw away the unused medicine in the vial. See Step 5.

For the latest PDR product information, visit PDP ne






Figure 16


3. Let go of the skin and slowly push down on the plunger past the resistance point, until the syringe is empty and you hear a click (Figure 17).



- 4. The click sound means that the needle (Figure 18) has been retracted (pulled back) into the syringe barrel (Figure 19).



5. Hold a cotton ball or gauze over the injection site (Figure 20). Do not rub the injection site. Apply an adhesive bandage to the injection site if needed.



- Step 5: Disposing of supplies
- Do not re-use a syringe or needle.
- Do not recap a used needle. • Place used needles, syringes and vials in a closeable, puncture-resistant container. You may use a sharps container (such as a red biohazard container), a hard plastic container (such as a detergent bottle), or a metal container (such as an empty coffee can). Ask your healthcare provider for instructions on the right way to throw away
- (dispose of) the contained. A start and the second syringes. If you have any questions, talk to your healthca vider or pharmacist. Wyeth® re pr Wyeth Pharmaceuticals Inc. Philadelphia, PA 19101 Under license from: Progenics Pharmaceuticals, Inc. Tarrytown, NY 10591 vie 11 A -sitteent SJER 10. A 1 Purdue Pharma L.P. bind sus **ONE STAMFORD FORUM** STAMFORD, CT 06901-3431 For Medical Inquiries: Adverse Drug Experiences FAX 800-877-3210 nie sozia a BUTRANS™ 3811991 10 1600 reca: [BYOO-trans] a bead (buprenorphine) Transdermal System for Transdermal Administration HIGHLIGHTS OF PRESCRIBING INFORMATION 1944 These highlights do not include all the information to use Butrans™ safely and effectively. See full prescribing information for Butrans. Butrans (buprenorphine) Transdermal System for the mal administration CIII Initial U.S. Approval: 1981 THE PROPERTY OF WARNING: POTENTIAL FOR ABUSE and IMPORTANCE OF PROPER PATIENT SELECTION to add and a second s See full prescribing information for complete boxed warning. Succession A Butrans is indicated for the management of it ate to severe chronic pain in patients requiring a con tinuous, around-the-clock opioid analgesic for an a tended period of time. (1) 00012 • Butrans contains buprenorphine which is asm opioid partial agonist and a Schedule III co substance. (9.1) Assess patients for their clinical risks for of abuse or addiction prior to prescribing oploids [22 Do not exceed a dose of one 20 mcg/hour Bu system due to the risk of QTc interval prolongati (2.3) Avoid exposing the Butrans application site an rounding area to direct external heat source Temperature-dependent increases in buprenorphin release from the system may result in overdean and death (21) hal said death. (5.11) INDICATIONS AND USAGE INDICATIONS AND USAGE Butrans is indicated for the management of mode are used vere chronic pain in patients requiring; atomimute around-the-clock opioid analgesic for an extended error time. (1) -DOSAGE AND ADMINISTRATION - Each, Butrans is intended to be used for the mode (2)

- Each Butrans is intended to be worn for *Tidaya* (20)
 In opioid-naïve 'patients, the initial dose of Birran should always be 5 mcg/hour. (2.2)
 For naïves chearted and the initial dose of the should always be for patients chearted and the should always be a statement of the should be always and the should be always be a should be always be always be a should b
- For patients already receiving opioids, consult conve • Do not increase the Butrans dose until the pene instructions. (2.2)
- been exposed continually to the previous do the hours. (2.3) After removal, wait a minimum of 3 weeks before an
- When Butrans is no longer required by the patients ing to the same site (2.1)
- the dose as part of a comprehensive treatment plan (20) DOSAGE FORMS AND STRENGTIS
- Transdermal system, 5 mcg/hour, 10 mcg/hour a 20 mcg/hour. (3)
- -CONTRAINDICATIONS Patients who have significant respiratory depression
 51 5 2 5.1, 5.2)

IMPORTANT NOTICE: Updated drug information is sent bi-monthly via the PDR® Update Insert. For monthly email updates, register at PDR at the PDR

plin

bients

who have severe bronchial asthma (4) who have or are suspected of having paralytic il-

(4, 5,16) who have known hypersensitivity to any of its ments or the active ingredient, buprenorphine (4) magement of acute pain or in patients who require management of acute pain or in patients who require managesia for a short period of time (4) nagement of post-operative pain, including use

namagement of mild pain (4)

and

Pro

€ Ŗ

ION

eeded

ribing

nsder

SYRIP

'OR-

oxed.

sder-

con

) ØX

071

belle

sioid

(2.2)

rans

tion.

SUI-

rces.

hine

and

de.

to se

auous.

riod of

:1)

ütrans

rersion

nt has

for 72

apply

, taper

a. (2.5)

; and

ion (4,

st.

13:35

management of intermittent pain (e.g., use on an as-basis (prn)) (4) WARNINGS AND PRECAUTIONS

with extreme caution in patients at risk of respiradepression. (5.1, 7.2)

- with caution in patients who are receiving other Inervous system (CNS) depressants. (5.2, 7.2, 12.2) CNS effects are expected when used with alcozodiazepines, other opioids, or illicit drugs. (5.3,
- in patients with Long QT Syndrome, family history QT Syndrome, or those taking Class IA or Class harrhythmic medications. (5.4, 12.2)
- me its signs, such as level of consciousness or pupilins may worsen increased intracranial pressure and
- with caution in patients at increased risk of hypom and in patients in circulatory shock. (5.6, 12.2) may occur. Monitor for decreased bowel motility in perative patients. (5.16)
- with cution in patients with biliary tract disease, in-ling acute pancreatitis. (5.16) ADVERSE REACTIONS

ommon adverse reactions (≥5%) include: nausea, the application site pruritus, dizziness, constipation, fence, vomiting, application site erythema, dry

and application site rash. Woort SUSPECTED ADVERSE REACTIONS, contact Pharma L.P. at 1-888-726-7535 or FDA at 1-800-FDAor www.fda.gov/medwatch.

- -DRUG INTERACTIONS
- Tents that induce CYP3A4 enzymatic activity may alter metabolism of buprenorphine but the clinical signifie of these interactions is not known. (7.1)
- AS depressants may interact with Butrans resulting in muratory and CNS depression - use caution in prescrib-Butrans for patients receiving benzodiazepines or depressants and warn patients against concomitant administration/misuse. (7.2)
- relevants may enhance the action of Butrans and
 - -USE IN SPECIFIC POPULATIONS
- remancy: Butrans is not recommended for use during remancy. (8.1) mining Mothers: Breast-feeding is not advised in moth-
- reated with Butrans. (8.3)
- diatric Use: Safety and effectiveness of Butrans have en established in patients below 18 years. (8.4) enatric Use: While no dose adjustment is recommended
- the basis of age, administer Butrans with caution in y patients. (8.5)
- matic Impairment: Butrans has not been evaluated in the with severe hepatic impairment and should be ministered with caution. (8.6)
- II for PATIENT COUNSELING INFORMATION Medication Guide. **Revised: August 2010**

AL PRESCRIBING INFORMATION: CONTENTS* **MED WARNING** INDICATIONS AND USAGE

DOSAGE AND ADMINISTRATION

- General Principles
- Initiation of Therapy Dose Titration
- Maintenance of Therapy and Supplemental Anal-
- gesia Cessation of Therapy

Patients with Hepatic Impairment

- DOSAGE FORMS AND STRENGTHS
- CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

- L Respiratory Depression
- CNS Depression 63
- Interactions with Alcohol, Central Nervous Sys-tem Depressants, and Illicit Drugs

QTc Prolongation 655

- Head Injury 5.6 Hypotensive Effects
- Misuse, Abuse, and Diversion of Opioids

RM

- Hepatotoxicity
- Application Site Skin Reactions 5.10 Anaphylactic/Allergic Reactions

- Application of External Heat 5.11 5.12Patients with Fever
- 5.13Driving and Operating Machinery
- 5.14Seizures
- 5.15Special Risk Groups
- Use in Pancreatic/Biliary Tract Disease and Other Gastrointestinal Conditions 5.16Use in Addiction Treatment 5.17
- 5.18 MAO Inhibitors
- ADVERSE REACTIONS
- **Clinical Trial Experience**
- 7 DRUG INTERACTIONS
- 7.1 Metabolic Drug Interactions
- 7.2 Non-Metabolic Drug Interactions USE IN SPECIFIC POPULATIONS
- Pregnancy 8.1 8.2

8

- Labor and Delivery 8.3
- Nursing Mothers Pediatric Use 8.4
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment
- **Renal Impairment** 8.7
- 88 Gender Differences DRUG ABUSE AND DEPENDENCE Controlled Substance 9.1
 - 9.2Abuse
- Physical Dependence and Tolerance 10 OVERDOSAGE
- 10.1 Symptoms 10.2 Treatment
- 11 DESCRIPTION
- CLINICAL PHARMACOLOGY
- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY
- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 14 CLINICAL STUDIES
- HOW SUPPLIED/STORAGE AND HANDLING
- PATIENT COUNSELING INFORMATION 17

17.1 Information for Patients and Caregivers *Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: IMPORTANCE OF PROPER PATIENT SELECTION POTENTIAL FOR ABUSE, LIMITATIONS OF USE Proper Patient Selection

Butrans is a transdermal formulation of buprenorphine indicated for the management of moderate to severe chronic pain in patients requiring a continuous, aroundthe-clock opioid analgesic for an extended period of time. (1)

Potential for Abuse

Butrans contains buprenorphine which is a mu opioid partial agonist and a Schedule III controlled substance. Butrans can be abused in a manner similar to other opioid agonists, legal or illicit. Consider the abuse potential when prescribing or dispensing Butrans in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. (9)

Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). Assess patients for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. Routinely monitor all patients receiving opioids for signs of misuse, abuse and addiction. (2.2)

Limitations of Use

Do not exceed a dose of one 20 mcg/hour Butrans system due to the risk of QTc interval prolongation. (2.3) Avoid exposing the Butrans application site and surrounding area to direct external heat sources. Temperature-dependent increases in buprenorphine release from the system may result in overdose and death. (5.11)

INDICATIONS AND USAGE 1

Butrans is indicated for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time.

- DOSAGE AND ADMINISTRATION 2
- **General Principles** 2.1

Selection of patients for treatment with Butrans is governed by the same principles that apply to the use of similar opioid analgesics. Physicians should individualize treatment in ev-Visit PDR.net to register for Product Safety Alerts and to download mobile PDR® - free to U.S. prescribers

Find authenticated court documents without watermarks at docketalarm.com.

ery case, using non-opioid analgesics, opioids on an asneeded basis and/or combination products, and chronic opioid therapy in a progressive plan of pain management such as outlined by the World Health Organization, the American Pain Society, and Federation of State Medical Boards Model Policy. Butrans is for transdermal use (on intact skin) only.

BUTRANS • PURDUE/2865

Do not use Butrans if the pouch seal is broken or the patch is cut, damaged, or changed in any way. Do not cut Butrans. Each Butrans is intended to be worn for 7 days.

Apply Butrans to the upper outer arm, upper chest, upper back or the side of the chest. These four sites (each present on both sides of the body) provide 8 possible application sites. Rotate Butrans among the 8 described skin sites. After Butrans removal, wait a minimum of 21 days before reapplying to the same skin site [see Clinical Pharmacology (12.3)1

Apply Butrans to a hairless or nearly hairless skin site. If none are available, the hair at the site should be clipped, not shaven. Do not apply Butrans to irritated skin. If the application site must be cleaned, clean the site with water only. Do not use soaps, alcohol, oils, lotions, or abrasive devices. Allow the skin to dry before applying Butrans.

If problems with adhesion of Butrans occur, the edges may If problems when database a few and a set of days dosing interval, dis-transfalls off during the 7 days dosing interval, dis-

pose of the transdermal system properly and place a new Butrans on at a different skin site [see How Supplied/Stor-age and Handling (16)].

verting patients from another opioid medication can result

in fatal overdose with the first dose [see Overdosage (10)].

Consider the following when selecting the initial dose of

1. The total daily dose, potency, and specific characteristics

of the opioid the patient has been taking previously;

2. The reliability of the relative potency estimate used to

3. The patient's degree of tolerance to the respiratory-

4. The age, general condition, and medical status of the pa-

5. Concurrent non-opioid analgesic and other medications; 6. The type and severity of the patient's pain;

7. The balance between pain control and adverse drug ex-

8. Risk factors for abuse, addiction, or diversion, including a

The following dosing recommendations, therefore, can only

be considered as suggested approaches to what is actually a

series of clinical decisions over time in the management of

For opioid-naïve patients, initiate treatment with Butrans

5 mcg/hour. Thereafter, individually titrate the dose as de-

scribed in Section 2.3 Dose Titration to a level that provides

adequate analgesia and minimizes side effects. Dose may be

titrated to the next higher level after a minimum of 72

There is a potential for buprenorphine to precipitate with-

drawal in patients who are already on opioids. For conver-sion from other opioids to Butrans (see Table 1), taper the

patient's current around-the-clock opioids for up to 7 days to

no more than 30 mg of morphine or equivalent per day be-fore beginning treatment with Butrans. Patients may use

short-acting analgesics as needed until analgesic efficacy

For patients whose daily dose was less than 30 mg of oral

morphine or equivalent, initiate treatment with Butrans

5 mcg/hour. For patients whose daily dose was between 30

and 80 mg morphice equivalents, initiate treatment with Butrans 10 mcg/hour (see Table 1). Thereafter, individually

titrate the dose as described in Section 2.3 Dose Titration.

Table 1: Dose Estimation for Conversion of Oral Morphine

Use caution when prescribing Butrans to opioid-

experienced patients requiring high doses of opioids (more

Current Daily Dose

30-80 mg

T

10 mcg/hour

<30 mg

T

5 mcg/hour

prior history of abuse, addiction, or diversion.

the pain of each individual patient.

Conversion from Other Opioids to Butrans

Opioid-Naïve Patients

with Butrans is attained.

Equivalents to Butrans

Current Opioid Analgesic

Oral Morphine Equivalent

Recommended Butrans

Starting Dose

depressant and sedating effects of opioids;

calculate the equivalent buprenorphine dose needed

(when converting from other opioids or opioid-

Initiation of Therapy It is critical to initiate the dosing regimen individually for each patient. Overestimating the Butrans dose when con-

combination products);

Butrans:

tient;

hours.

eriences

than 80 mg/day of oral morphine equivalents). Butrans 20 mcg/hour may not provide adequate analgesia for patients requiring greater than 80 mg/day oral morphine equivalents.

Dose Titration 2.3

Based on the patient's requirement for supplemental shortacting analgesics, upward titration may be instituted with a minimum Butrans titration interval of 72 hours, based on the pharmacokinetic profile and time to reach steady state levels [see Clinical Pharmacology (12.3)]. Individually titrate the dose, under close supervision, to a level that provides adequate analgesia with tolerable side effects.

The maximum Butrans dose is 20 mcg/hour. Do not exceed a dose of one 20 mcg/hour Butrans system due to the risk of QTc interval prolongation. In a clinical trial, Butrans 40 mcg/hour (given as two Butrans 20 mcg/hour systems) resulted in prolongation of the QTc interval [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.2)]. During periods of changing analgesic requirements, including initial titration, frequent contact is recommended between the prescriber, other members of the healthcare team, the patient, and the caregiver/family. Advise patients and caregivers/family members of the potential side effects. 2.4 sia Maintenance of Therapy and Supplemental Analge-

The intent of the titration period is to establish a patientspecific weekly Butrans dose that will maintain adequate analgesia with tolerable side effects for as long as pain management is necessary. Immediate-release opioid and nonopioid medications can be used as supplemental analgesia during Butrans therapy.

During chronic opioid analgesic therapy with Butrans, reassess the continued need for around-the-clock opioid analgesic therapy periodically.

Cessation of Therapy 25

When the patient no longer requires therapy with Butrans, taper the dose gradually to prevent signs and symptoms of withdrawal in the physically-dependent patient; consider introduction of an appropriate immediate-release opioid medication. Undertake discontinuation of therapy as part of a comprehensive treatment plan.

Patients with Hepatic Impairment

Start patients with mild to moderate hepatic impairment with the Butrans 5 mcg/hour dose. Thereafter, individually titrate the dose to a level that provides adequate analgesia and tolerable side effects, under the close supervision of the prescriber. Butrans has not been evaluated in patients with evere hepatic impairment. As Butrans is only intended for 7-day application, consider use of an alternate analgesic that may permit more flexibility with the dosing in patients with severe hepatic impairment (see Warnings and Precau-tions (5.1), Use In Specific Populations (8.6), and Clinical Pharmacology (12.3)].

DOSAGE FORMS AND STRENGTHS 8

Butrans is available as:

- Butrans 5 mcg/hour Transdermal System (dimensions: 45 mm by 45 mm)
- Butrans 10 mcg/hour Transdermal System (dimensions) 45 mm by 68 mm) • Butrans 20 mcg/hour Transdermal System (dimensions:
- 72 mm by 72 mm)

4 CONTRAINDICATIONS

- Butrans is contraindicated in:
- · patients who have significant respiratory depression
- patients who have severe bronchial asthma
- patients who have or are suspected of having paralytic ileus
- · patients who have known hypersensitivity to any of its components or the active ingredient, buprenorphine • the management of acute pain or in patients who require
- opioid analgesia for a short period of time • the management of post-operative pain, including use af-
- ter out-patient or day surgeries
- the management of mild pain

DOCKE.

• the management of intermittent pain (e.g., use on an as needed basis [prn])

WARNINGS AND PRECAUTIONS

5.1 **Respiratory Depression** Respiratory depression is the chief hazard of Butrans, Respiratory depression occurs more frequently in elderly or debilitated patients as well as those suffering from conditions accompanied by hypoxia or hypercapnia when even moderate therapeutic doses may dangerously decrease pulmonary ventilation, and when opioids, including Butrans, are given in conjunction with other agents that depress respiration.

Profound sedation, unresponsiveness, infrequent deep ("sighing") breaths or atypical snoring frequently accompany opioid-induced respiratory depression. Use Butrans with extreme caution in patients with any of

the following:

 significant chronic obstructive pulmonary disease or cor pulmonale

- other risk of substantially decreased respiratory reserve such as asthma, severe obesity, sleep apnea, myxedema, clinically significant kyphoscoliosis, and central nervous system (CNS) depression
- hypoxia hypercapnia
- · pre-existing respiratory depression
- 5.2 CNS Depression

Butrans may cause somnolence, dizziness, alterations in judgment and alterations in levels of consciousness, including coma.

Interactions with Alcohol, Central Nervous System 5.3 Depressants, and Illicit Drugs

Hypotension, profound sedation, coma or respiratory depression may result if Butrans is added to a regimen that includes other CNS depressants (e.g., sedatives, anxiolytics, hypnotics, neuroleptics, muscle relaxants, other opioids). Therefore, use caution when deciding to initiate therapy with Butrans in patients who are taking other CNS depressants. Take into account the types of other medications be-ing taken, the duration of therapy with them, and the patient's response to those medicines, including the degree of tolerance that has developed to CNS depression. Consider the patient's use, if any, of alcohol and/or illicit drugs that e CNS depression. If the decision to begin Butrans is made, start with a lower Butrans dose than usual.

Consider using a lower initial dose of a CNS depressant when given to a patient currently taking Butrans due to the potential of additive CNS depressant effects. 5.4 QTc Prolongation

A positive-controlled study of the effects of Butrans on the QTc interval in healthy subjects demonstrated no clinically meaningful effect at a Butrans dose of 10 mcg/hour: however, a Butrans dose of 40 mcg/hour (given as two Butrans 20 mcg/hour Transdermal Systems) was observed to prolong the QTc interval [see Clinical Pharmacology (12.2)].

Consider these observations in clinical decisions when prescribing Butrans to patients with hypokalemia or clinically unstable cardiac disease, including: unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia. Avoid the use of Butrans in patients with a history of Long QT Syndrome or an immediate family member with this condition, or those taking Class IA antiarrhythmic medications (e.g., quinidine, procainamide, disopyramide) or Class III antiarrhythmic medications (e.g., sotalol, amiodarone, dofetilide).

5.5 Head Injury

The respiratory depressant effects of opioids, including Butrans, include carbon dioxide retention, which can lead to an elevation of cerebrospinal fluid pressure. This effect may be exaggerated in the presence of head injury, intracranial lesions, or other sources of pre-existing increased intracranial pressure. Butrans may produce miosis that is indepen-dent of ambient light, and altered consciousness, either of which may obscure neurologic signs associated with increased intracranial pressure in persons with head injuries. Hypotensive Effects 5.6

Butrans may cause severe hypotension. There is an added risk to individuals whose ability to maintain blood pressure has been compromised by a depleted blood volume, or after concurrent administration with drugs such as phenothiazines or other agents which compromise vasomotor tone. Buprenorphine may produce orthostatic hypotension in ambulatory patients. Administer Butrans with caution to patients in circulatory shock, since vasodilation produced by the drug may further reduce cardiac output and blood pressure.

5.7 Misuse, Abuse, and Diversion of Opioids

Butrans contains buprenorphine, a partial agonist at the mu opioid receptor and a Schedule III controlled substance. Opioid agonists have potential for being abused, are sought by drug abusers and people with addiction disorders, and are subject to criminal diversion.

Butrans can be abused in a manner similar to other opioid agonists, legal or illicit. Consider this potential for abuse when prescribing or dispensing Butrans in situations where the prescriber or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Monitor all paents receiving opioids for signs of abuse, misuse, and diction. Furthermore, assess patients for their potential for opioid abuse prior to being prescribed opioid therapy. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse) or mental illness (e.g., depression). Opioids may still be appropriate for use in these patients; however, they will require intensive monitoring for signs of abuse.

Notwithstanding concerns about abuse, addiction, and di version, provide proper management of pain. However, all patients treated with opioid agonists require careful monitoring for signs of abuse and addiction, since use of opioid agonist analgesic products carries the risk of addiction even under appropriate medical use [see Drug Abuse and Depen-

dence (9.2)]. Data are not available to establish the set cidence of addiction in patients with chronic pain be with opioids. Pater

Abuse of Butrans poses a significant risk to the ab could potentially result in overdose or death (see b) Abuse and Dependence (9)].

Contact your state professional licensing board or state trolled substances authority for information on board how to pa vent and detect abuse or diversion of this product.

vent and detect abuse or unversion of the product. 5.8 Hepatotoxicity Although not observed in Butrans chronic pain clinical is als, cases of cytolytic hepatitis and hepatitis with jained have been observed in individuals receiving sublead buprencryphine for the treatment of opioid dependence in the although post-marketing adverse. buprenorphine for the treasured to prive dopendence bai in clinical trials and through post-marketing adverse end reports. The spectrum of abnormalities ranges for the sient asymptomatic elevations in hepatic transamination sient asymptomatic elevations in negatic transaminate case reports of hepatic failure, hepatic necrosis, hepational syndrome, and hepatic encephalopathy. In many case to presence of pre-existing liver enzyme abnormalities, ind-tion with hepatitis B or hepatitis C virus, conomiz-tion with hepatitis B or hepatitocic drugs, and ontion with hepatitis B or hepatitis C virus, concontin-usage of other potentially hepatotoxic drugs, and one injection drug abuse may have played a causative of the tributory role. In other cases, insufficient data were sail able to determine the etiology of the abnormality The pu-thility against the hunrenorrobine had a causative sibility exists that buprenorphine had a causative contributory role in the development of the hepatic and mality in some cases. For patients at increased risk of he atotoxicity (e.g., patients with a history of excessive along intake, intravenous drug abuse or liver disease), baselin and periodic monitoring of liver function during treatment with Butrans is recommended. A biological and etiological evaluation is recommended when a hepatic event is an

pected. <u>Б</u>9 Application Site Skin Reactions

In rare cases, severe application site skin reactions with In rare cases, severe application site only reactions will signs of marked inflammation including "burn," dischares, and "vesicles" have occurred. Time of onset varies, range from days to months following the initiation of Butran treatment. Instruct patients to promptly report the development of severe application site reactions and discontinue therapy.

Cases of acute and chronic hypersensitivity to buprenorphine have been reported both in clinical trials and in the post-marketing experience. The most common size and symptoms include rashes, hives, and pruritus. Case of bronchospasm, angioneurotic edema, and anaphylatic shock have been reported. A history of hypersensitivity to buprenorphine is a contraindication to the use of Butrans. 5.11 Application of External Heat

Advise patients and their caregivers to avoid exposing the Advise patients and their caregivers to avoid exposing the Butrans application site and surrounding area to direct ternal heat sources, such as heating pads or electric bla-kets, heat or tanning lamps, saunas, hot tubs, and heat water beds, etc., while wearing the system because an in-crease in absorption of buprenorphine may occur [see Clin-ical Pharmacology (12.3)]. Advise patients against exposure of the Durance configuration of and surrounding gotthe of the Butrans application site and surrounding area to hot water or prolonged exposure to direct sunlight. There is a potential for temperature-dependent increases in buprenorphine released from the system resulting in possble overdose and death.

5.12 **Patients with Fever**

Patients wearing Butrans systems who develop fever or in-creased core body temperature due to strenuous exertion should be monitored for opioid side effects and the Butrans dose should be adjusted if necessary [see Dosage and Ad-ministration (2.4)].

5.13 Driving and Operating Machinery Butrans may impair the mental and physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Caution patients ac cordingly.

Seizures 5.14

Butrans, as with other opioids, may aggravate seizure dis-orders, may lower seizure threshold, and therefore, may in-duce seizures in some clinical settings. Use Butrans with caution in patients with a history of seizure disorders. Special Risk Groups 5.15

Use Butrans with caution in the following conditions, due to increased risk of adverse reactions: alcoholism; delirium tremens; adrenocortical insufficiency; CNS depression; de-bilitation; kyphoscoliosis associated with respiratory compromise; myxedema or hypothyroidism; prostatic hypertro-phy or urethral stricture; severe impairment of hepatic, pulmonary or renal function; and toxic psychosis: 5.16 Use in Pancreatic/Siliary Tract Disease and Other Gastrointesting! Condition

Gastrointestinal Conditions

Butrans may cause spasm of the sphincter of Oddi. Use with caution in patients with biliary tract disease, including acute pancreatitis. Opioids, including Butrans, may cause increased serum amylase.

The administration of Butrans may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Use Butrans with caution in patients who are at risk of de veloping ileus.

5.17 Use in Addiction Treatment Butrans has not been studied and is not approved for use in the management of addictive disorders.

IMPORTANT NOTICE: Updated drug information is sent bi-monthly via the PDR® Update Insert. For monthly email updates, register at PDR.net.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.